Landos Biopharma: Landos Biopharma is a clinical-stage biopharmaceutical company which uses its LANCE A.I. platform to discover and develop novel, first-in-class oral therapeutics for autoimmune diseases. Lead asset omilancor (BT-11) is a Phase 3-ready orally-active, gut-restricted candidate for treatment of ulcerative colitis also targeting Crohn’s disease and IBS. NX-13 is a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway (UC Ph1b initiated 2Q21, topline data 1H22). Additional candidates are in development for the treatment of lupus nephritis (IND accepted in Oct. 2021), rheumatoid arthritis, multiple sclerosis, and diabetes. Partnership with LianBio to develop and commercialize Omilancor and NX-13 in greater China and select Asian markets announced May 2021.